Downstream Bioprocessing 2021

COVID-19 vaccine approvals: key lessons for mRNA therapeutics

Cell & Gene Therapy Insights 2021; 7(11), 2059-7800

DOI: 10.18609/cgti.2021.209

Published: 6 December 2021
Poster
Venkata Indurthi, PhD, Joseph Barberio, Scott Zobbi, Dr. Christoph Kröner

The development of mRNA therapeutics is not a new phenomenon, but the key role played by mRNA-based vaccines in battling the COVID-19 pandemic has resulted a rapid acceleration in the development timeframe of this technology field. In a recent expert roundtable discussion, we spoke to a panel of experts within the field to better understand what lessons the vaccine and therapeutic fields can learn from each other. Here, we sum up some of their key thoughts.

Venkata Indurthi

Vice President Research and Development, Aldevron

Venkata SK Indurthi, PhD is the Vice President of research and development at Aldevron (est. 1998, www.aldevron.com), a biologicals CDMO with sites in Fargo ND and Madison WI. He received his bachelor’s in engineering in biotechnology from SRM university (Chennai, India) and his Ph.D. in Pharmaceutical Sciences from North Dakota State University (Fargo, ND). After completing graduate school, he joined Aldevron as an assay development scientist and was focused developing assay for GMP release for biologics (DNA, RNA and protein). He then transitioned to a role of senior scientist, Product and Process Design (PPD) where he led the development of Aldervon’s mRNA process and platform and more recently as the Director of R&D where he established all the R&D efforts for Aldevron. Dr. Indurthi leads efforts that to develop new platforms and innovative manufacturing processes for the company including (not limiting to) the mRNA platform, plasmid DNA, gene synthesis and cell free synthetic DNA platform. His team also focuses on the development of new products for the company such as enzymes with improved attributes (increased yield, stability or activity). Dr. Indurthi’s research interests focus on the development of biologics. Particularly, new platform development from idea conception to commercialization. He has developed processes that are currently used for GMP manufacturing. Dr. Indurthi is also the operational head for the Aldevron RNA services.

Joseph Barberio

Director, Process Development, Strand Therapeutics Inc.

Joseph Barberio is a biochemist and molecular biologist with a proven track record of solving complex problems with innovative solutions. He is the Director of mRNA Process Development at Strand Therapeutics and oversees Strand’s manufacturing strategy to support clinical development. With over fifteen years of industry experience, Joe specializes in process and analytical development and has extensive expertise in manufacturing of both viral and RNA based gene therapy medicinal products. The majority of Joseph’s career has been focused on building platforms for small biotech organizations. Most recently at bluebird bio, he constructed and led the mRNA process development team, a group designed to enable gene editing programs. Earlier in his career, Joe held process development roles at Moderna, Percivia, and Acceleron Pharma. In addition to his work at Strand, Joseph also serves on the Board of Directors of Sophie’s Hope Foundation, a non-profit charity supporting research for glycogen storage disease type 1b (GSD1b).

Scott Zobbi

Senior Business Development Manager, Custom POROS Chromatography Resins, Thermo Fisher Scientific

Scott Zobbi is a Senior Manager of Business Development for Custom POROS Resins within the Bioproduction Division at Thermo Fisher Scientific. Scott has a B.S. in Biology from University of Connecticut and an MBA from the University of Massachusetts. Scott has worked on chromatography applications in the biotech industry for decades with 22 years spent at Thermo Fisher Scientific. His expertise is finding solutions to complex separation challenges draws on his experience in cGMP manufacturing, process development, customer training, sales and product management. In his current role, Scott is responsible for managing globally the Custom POROS Resin program, including working with customers to identify needs, in-house R&D to develop solutions, and POROS manufacturing to commercialize bioprocess resins for GMP applications.

Dr Christoph Kröner

Director, DNA Process Development & Cap Technology, BioNTech SE

Christoph Kröner works as Director DNA Process Development & Cap Technology at BioNTech RNA Pharmaceuticals GmbH with strong focus on developmental work for BioNTech’s various clinical projects using mRNA as drug substance. He has more than 10 years of experience working with nucleic acids like mRNAs. His work focused on mRNA-based therapeutics when he joined BioNTech in 2014 as a scientist. Christoph Kröner holds a diploma and PhD in chemistry from the University of Stuttgart, Germany.


To find out more, read the full discussion here.

You can also  download and print the poster here